Ketamine for the Treatment for Alcohol Use Disorder in the ED

Randomised, triple-blind, parallel-group trial comparing a single IV ketamine infusion (0.8 mg/kg, 40 minutes) with saline placebo in individuals presenting to the ED for inpatient alcohol detoxification; primary aim is safety.

Secondary measures include alcohol use outcomes (TLFB abstinent days, days to relapse, heavy drinking days), engagement with addiction treatment, urine ketamine, and alcohol biomarkers at 28 days.